On September 13, 2023, Aaron Fletcher, Ph.D. advised the Board of Directors of TFF Pharmaceuticals, Inc. of his decision not to stand for reelection to the Board at the Company?s 2023 annual meeting of stockholders, to be held later this year. Dr. Fletcher?s decision to resign from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices. Dr. Fletcher is the Managing Partner of Bios Partners, a venture capital firm focused on investment in early-stage and growth-stage biotech companies.

Dr. Fletcher advised the Board that his decision not to stand for reelection is due to a recently adopted policy of Bios Partners restricting its partners from serving on the board of directors of a public company unless the company received a direct investment from a Bios fund prior to going public. Dr. Fletcher intends to remain on the Board of the Company until his present term expires upon the conclusion of the Company?s 2023 annual meeting of stockholders.